Literature DB >> 11085287

ET gets HIT--thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET).

L Risch1, H Pihan, C Zeller, A R Huber.   

Abstract

Immune-mediated heparin-induced thrombocytopenia (HIT) is a relatively common complication in patients receiving heparin, and represents a strong risk factor for thromboembolic disease associated with high morbidity and mortality. The condition is commonly defined as a platelet count fall of greater than 30-50% to values below 150 x 10(9)/l. Despite this, several cases with platelet count nadirs in the normal range have been reported. This report describes a patient with status post-carotid thrombendarterectomy presenting with neurological symptoms and thrombocytosis (1235 x 10(9)/l), which in due course was diagnosed to be caused by essential thrombocythemia (ET). Heparin therapy was established and symptoms resolved markedly. After 5 days of standard heparin therapy, serologically confirmed HIT with new neurological symptoms occurred. The platelet count nadir attributed to HIT was far above normal (633 x 10(9)/l), which nevertheless represented a substantial relative platelet count fall (49%). This is the first reported case of serologically confirmed HIT in a patient with ET. Furthermore, it represents the first published case of HIT being present in thrombocytosis. Clinicians should be aware that atypical HIT can even be present in thrombocytosis and, because of nomenclature, HIT with normal and elevated platelet count nadirs is likely to be largely underdiagnosed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085287     DOI: 10.1097/00001721-200010000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Heparin-induced thrombocytopenia associated with polycythemia vera during the treatment of acute coronary syndrome.

Authors:  Takashi Yoshizane; Makoto Iwama; Takahiro Ueno; Maya Ishiguro; Yoshiaki Goto; Koji Ono; Masazumi Arai; Toshiyuki Noda
Journal:  J Cardiol Cases       Date:  2016-04-28

Review 2.  Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes.

Authors:  Lorenz Risch; Joachim E Fischer; Roberto Herklotz; Andreas R Huber
Journal:  Intensive Care Med       Date:  2004-05-19       Impact factor: 17.440

3.  Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction.

Authors:  Apoorva Jayarangaiah; Narendranath Epperla
Journal:  BMJ Case Rep       Date:  2015-11-04

4.  Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Authors:  Sara C Meyer; Eva Steinmann; Thomas Lehmann; Patricia Muesser; Jakob R Passweg; Radek C Skoda; Dimitrios A Tsakiris
Journal:  Biomed Res Int       Date:  2017-06-18       Impact factor: 3.411

5.  Heparin-Induced Thrombocytopenia in a Patient with Essential Thrombocythemia: A Case Based Update.

Authors:  Edva Noel; Naeem Abbas; Yevegeniy Skaradinskiy; Zwi Schreiber
Journal:  Case Rep Hematol       Date:  2015-10-22

6.  What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations.

Authors:  Marie-Camille Soucy-Giguère; Pierre Yves Turgeon; Mario Sénéchal
Journal:  Int Med Case Rep J       Date:  2019-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.